AKR1A1
Aldo-keto reductase family 1 member A1
Also known as: AK1A1_HUMAN, ALR, DD3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P14550
- Gene
- AKR1A1
- Ensembl
- ENSG00000117448
- Chromosome
- 1
- Canonical length
- 325 aa
- Protein class
- Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member, also known as aldehyde reductase, is involved in the reduction of biogenic and xenobiotic aldehydes and is present in virtually every tissue. Multiple alternatively spliced transcript variants of this gene exist, all encoding the same protein. [provided by RefSeq, Jan 2011]
Canonical amino-acid sequenceUniProt
325 residues, UniProt reviewed canonical sequence.
>P14550|AKR1A1
1 MAASCVLLHT GQKMPLIGLG TWKSEPGQVK AAVKYALSVG YRHIDCAAIY GNEPEIGEAL
61 KEDVGPGKAV PREELFVTSK LWNTKHHPED VEPALRKTLA DLQLEYLDLY LMHWPYAFER
121 GDNPFPKNAD GTICYDSTHY KETWKALEAL VAKGLVQALG LSNFNSRQID DILSVASVRP
181 AVLQVECHPY LAQNELIAHC QARGLEVTAY SPLGSSDRAW RDPDEPVLLE EPVVLALAEK
241 YGRSPAQILL RWQVQRKVIC IPKSITPSRI LQNIKVFDFT FSPEEMKQLN ALNKNWRYIV
301 PMLTVDGKRV PRDAGHPLYP FNDPYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AKR1A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.22
- Highest tissue expression
- 302 nTPM
Expression across tissuesHPA
Tissue
- liver: 302 nTPM
- kidney: 302 nTPM
- duodenum: 178 nTPM
- small intestine: 162 nTPM
- pancreas: 135 nTPM
- esophagus: 133 nTPM
Single-cell type
- enterocytes: 812 nCPM
- breast lactating cells: 609 nCPM
- hofbauer cells: 567 nCPM
- esophageal apical cells: 400 nCPM
- esophageal suprabasal cells: 399 nCPM
- respiratory secretory cells: 324 nCPM
Immune cell
- classical monocyte: 230 nTPM
- intermediate monocyte: 225 nTPM
- myeloid DC: 197 nTPM
- total PBMC: 183 nTPM
- non-classical monocyte: 175 nTPM
- plasmacytoid DC: 170 nTPM
Brain region
- white matter: 63 nTPM
- choroid plexus: 54 nTPM
- thalamus: 46 nTPM
- medulla oblongata: 45 nTPM
- spinal cord: 42 nTPM
- pons: 41 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.12
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.02
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- aldehyde catabolic process
- cellular detoxification of aldehyde
- D-glucuronate catabolic process to D-xylulose 5-phosphate
- daunorubicin metabolic process
- doxorubicin metabolic process
- glutathione derivative biosynthetic process
- lipid metabolic process
- negative regulation of apoptotic process
Molecular functions
- alcohol dehydrogenase (NADP+) activity
- aldose reductase (NADPH) activity
- allyl-alcohol dehydrogenase activity
- glycerol dehydrogenase (NADP+) activity
- L-glucuronate reductase activity
- methylglyoxal reductase (NADPH) (acetol producing) activity
- S-nitrosoglutathione reductase (NADH) activity
- S-nitrosoglutathione reductase (NADPH) activity
- glucuronolactone reductase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AKR1A1 as an antibody target. Whether an autoantibody or antibody against AKR1A1 could matter depends on whether native AKR1A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AKR1A1 is annotated at the cell surface, where native AKR1A1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label AKR1A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...